Supernus Pharmaceuticals (SUPN) Assets Average (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Assets Average data on file, last reported at $1.5 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $1.5 billion, up 8.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 8.77% YoY), and the FY2025 annual result was $1.4 billion, up 6.61% from the prior year.
• Assets Average improved to $1.5 billion in Q1 2026 per SUPN's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Assets Average peaked at $1.7 billion in Q1 2023 and troughed at $1.3 billion in Q4 2023.
• A 5-year average of $1.5 billion and a median of $1.4 billion in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2024: Assets Average gained 10.53% in 2022, then declined 26.12% in 2024.
• A 5-year view of Assets Average shows it stood at $1.7 billion in 2022, then dropped by 24.53% to $1.3 billion in 2023, then climbed by 5.77% to $1.4 billion in 2024, then climbed by 5.96% to $1.4 billion in 2025, then grew by 2.82% to $1.5 billion in 2026.
• Business Quant data shows SUPN's Assets Average at $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.